ELLA

(redirected from ulipristal)
Also found in: Dictionary, Medical, Wikipedia.

ELLA

A hardware design language from DRA Malvern. Implemented in ALGOL68-RS.

E-mail: <ella@dra.hmg.gb>. SPARC version.

["ELLA 2000: A Language for Electronic System Design", J.D. Morison and A.S. Clarke, McGraw-Hill 1993].
References in periodicals archive ?
HRA Pharma specifically developed ellaOne (ulipristal acetate) to deliver a more advanced form of emergency contraceptive than that which was previously available.
Ulipristal acetate: a new emergency contraceptive that is safe and more effective than levonorgestrel.
The indication also includes the statement that ulipristal "is not intended for routine use as a contraceptive."
Participants were randomly assigned to receive either 30 mg of ulipristal acetate or 1.5 mg of levonorgestrel during the clinic visit, and were asked to keep a daily diary of subsequent acts of intercourse, contraceptive use, vaginal bleeding, medication use and adverse events.
They compared ulipristal with levonorgestrel in women with regular menstrual cycles who presented to a participating family planning clinic requesting emergency contraception within 5 days of unprotected sexual intercourse.
The availability of ulipristal acetate (Ella) for emergency contraception is limited (either immediately or via order placement), according to a national secret shopper telephone survey of 344 retail pharmacies in 10 major US cities.
Meanwhile, the Food and Drug Administration extended the PDUFA date for Allergan's uterine fibroid candidate, ulipristal acetate, with Credit Suisse analyst Vamil Divan arguing it may raise concerns over a potential regulatory rejection.
The COC (Yuzpe) regimen was the most commonly mentioned method (82.5%), while ulipristal acetate was the least mentioned (0.4%).
In this context, selective progesterone receptor modulators (SPRMs), such as ulipristal acetate, have been proposed for preoperative treatment.
SALT LAKE CITY -- The selective progesterone receptor modulator ulipristal acetate significantly reduced bleeding associated with fibroids in VENUS-I, a pivotal phase III trial of 147 premenopausal women.